{"contentid": 488641, "importid": NaN, "name": "Viatris\u00e2\u0080\u0099 1st-qtr 2021 financials beat expectations", "introduction": "Recently-formed Viatris, the combination of Mylan with Pfizer\u00e2\u0080\u0099s Upjohn business, has reported results for the first quarter of 2021, which demonstrate the strength of its differentiated operating platform and commercial capabilities, its broad and diverse product portfolio and its strong R&D platform, the company said.", "content": "<p>Recently-formed Viatris (Nasdaq: VTRS), the combination of Mylan with Pfizer&rsquo;s (NYSE: PFE) Upjohn business, has reported results for the first quarter of 2021, which demonstrate the strength of its differentiated operating platform and commercial capabilities, its broad and diverse product portfolio and its strong R&amp;D platform, the company said.</p>\n<p>First quarter 2021 net sales totaled $4.40 billion, down 6% compared to combined adjusted first-quarter 2020 results, but only down 2% compared to combined loss of exclusivity (LOE) adjusted Q1 2020 results driven by solid performance across all four of our segments - Developed Markets, Emerging Markets, JANZ (Japan, Australia and New Zealand), and Greater China. The sales figure beat expectations by 5.6%.</p>\n<p>Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) grew 118% year-on-year to $1.6 billion (reported), a decline of 10% compared to combined adjusted results.</p>\n<p>Adjusted net income rose 139% YoY to $1.1 billion. Adjusted earnings per share (EPS) of $0.92 beats consensus of $0.80. Generally accepted accounting principles (GAAP) net loss was $1 billion, or ($0.86) compared to net income of $20.8 million, or ($0.04) in first-quarter 2020.</p>\n<p><strong>2021 Financial Guidance</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p><strong>Range (billions)</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p><strong>Midpoint (billions)</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Total Revenue</p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>$17.2 - $17.8</p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>$17.5</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adjusted EBITDA</p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>$6.0 - $6.4</p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>$6.2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Free Cash Flow</p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>$2.0 - $2.3</p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>$2.15</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Following the latest results, Viatris' 13 analysts are now forecasting revenues of $17.6 billion in 2021.</p>\n<p>Brands performed better with a revenue increase of 157% on reported basis over prior year, driven by products such as: Lipitor (atorvastatin) at $464.6 million, Viagra (sildenafil) at $139.6 million, EpiPen (epinephrine) at $103.7 million, Norvasc (amlodipine) at $227.7 million, Lyrica (pregabalin) at $187.8 million and Amitiza (lubiprostone) at $45.9 million.</p>\n<p>Complex Generics and Biosimilars grew by 30% on reported basis and 27% compared to combined adjusted results, largely driven by pegfilgrastim, trastuzumab and adalimumab biosimilars. Generics revenues reached $1.3 billion, up 6% on reported and down 8% on combined adjusted basis.</p>\n<p>Michael Goettler, chief executive stated: \"Our strong first-quarter performance across revenue, adjusted EBITDA and free cash flow highlights the diversified and robust business profile that differentiates Viatris as a company. We see underlying strength in our business and we are reaffirming guidance for 2021, which incorporates known and potential headwinds and tailwinds for the remainder of the year. At the conclusion of the second quarter, we will be reassessing our guidance for the full year.\"</p>", "date": "2021-05-15 14:41:00", "meta_title": "Viatris\u00e2\u0080\u0099 1st-qtr 2021 financials beat expectations", "meta_keywords": "Viatris, First-quarter, 2021 Financials results", "meta_description": "Viatris\u00e2\u0080\u0099 1st-qtr 2021 financials beat expectations", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-15 14:40:41", "updated": "2021-05-15 14:48:12", "access": NaN, "url": "https://www.thepharmaletter.com/article/viatris-1st-qtr-2021-financials-beat-expectations", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "viatris_large.png", "image2id": "viatris_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biosimilars, Generics", "therapy area_tag": NaN, "topic_tag": "Financial", "geography_tag": "USA", "company_tag": "Viatris", "drug_tag": "Lipitor, Norvasc, Viagra", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-15 14:41:00"}